Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Resonance Health Reports Liver Fibrosis Results, Secures AU$6 Million Placement and Outlines Growth Plans
Highlights
Resonance Health Reports Preliminary Liver Fibrosis Results
Resonance Health Limited (ASX: RHT) has reported preliminary findings from its DEVIMLA study while outlining plans to expand its medical imaging technology and clinical trial operations. Resonance Health’s share price declined 8.536% to AU$0.075.
The research assessed Fibrosis Assessment, investigational software designed to assess liver fibrosis using standard magnetic resonance imaging (MRI) sequences without requiring additional scanner hardware. Preliminary analysis of 50 participants from the China study site recorded an AUROC of 0.82 for significant fibrosis, with 80% specificity and 75% sensitivity. For advanced fibrosis, the software achieved an AUROC of 0.79, with 93.5% specificity and 57.9% sensitivity. The broader study enrolled 68 adults across China, Malaysia and India. These results are preliminary and are yet to undergo independent verification. The technology has not been cleared for clinical use.
AU$6 Million Placement to Fund Growth
Resonance Health secured commitments for an oversubscribed AU$6 million share placement involving approximately 83.3 million new shares. The proceeds will help finance planned business expansion and cover the company’s ongoing funding needs. Planned allocations include AU$1.2 million for MRI endpoint development, AU$1.5 million for Trials West’s east coast expansion, AU$1.5 million for liver fibrosis validation and regulatory activities, AU$1.4 million for working capital and AU$0.4 million for placement costs.
Following the placement, the company expects pro forma cash of AU$10.4 million and net cash of AU$7.9 million. Settlement is expected on 6 November 2026, with allotment and trading of new shares scheduled for 9 November 2026.
Financial Performance and FY2027 Outlook
For FY2026, Resonance Health reported revenue of AU$15.8 million, up 42%, statutory net profit after tax of AU$1.5 million and operating cash inflow of AU$2.9 million.
For FY2027, management provided revenue guidance of AU$17 million to AU$22 million and EBITDA guidance of AU$2.6 million to AU$3.6 million. Priorities include MRI endpoint development, further liver fibrosis validation, regulatory engagement and expansion of clinical trial services. Progress will depend on execution of the company’s growth plans and further validation and regulatory work.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au